Da Hee Han, PharmD

Most Recent Articles by Da Hee Han, PharmD

Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation

Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation

By

NRX-101 combines D-cycloserine (DCS), an N-methyl-D-aspartate (NMDA) receptor antagonist, and lurasidone, a D2/5-HT2a receptor antagonist.

Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain

Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain

By

Researchers at the National Institute of Environmental Health Sciences (NIEHS), Vanderbilt University Medical Center, and the Henry Ford Health System analyzed patient data from African-American women aged 23 to 35 years (N=1553) who were participating in the NIEHS Study of Environment, Lifestyle, and Fibroids (SELF).

Bijuva Approved for Moderate to Severe Vasomotor Symptoms From Menopause

Bijuva Approved for Moderate to Severe Vasomotor Symptoms From Menopause

By

Approval from the Food and Drug Administration (FDA) was supported by the Phase 3 Replenish trial which evaluated the safety and efficacy of Bijuva in generally healthy, postmenopausal women with a uterus for the treatment of moderate to severe hot flashes.

Liletta Now Approved for Pregnancy Prevention for Up to 5 Years

Liletta Now Approved for Pregnancy Prevention for Up to 5 Years

By

The expanded approval was supposed by safety and efficacy data from the Phase 3 ACCESS IUS trial (N=1751) in women receiving Liletta. In the trial, Liletta demonstrated >99% efficacy in preventing pregnancy for up to 5 years in a broad patient population.

Talzenna Approved for Germline <i>BRCA</i>-Mutated, <i>HER2</i>-Negative Breast Cancer

Talzenna Approved for Germline BRCA-Mutated, HER2-Negative Breast Cancer

By

Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).

More Articles by Da Hee Han, PharmD

Sign Up for Free e-newsletters